Company / Shareholders' Equity
Inhibikase Therapeutics, Inc. Shareholders' Equity History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$11.0M
FY2024
5-year range
$9.8M / $38.4M
FY2021-FY2024
Trend
-47.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $38M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2024 with a 3-year CAGR of +3.9%.
Declined from $38M to $11M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +3.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +3.9%, indicating consistent growth.
- In FY2024, shareholders' equity decreased 47.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $11.0M | -47.8% |
| FY2023 | $21.0M | -45.2% |
| FY2022 | $38.4M | +292.6% |
| FY2021 | $9.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026